px Scrolled

Archive for the ‘Press Releases’ Category

Omni One, LLC signed an agreement today with CustomQuest

Posted by

Omni One, LLC signs agreement today with CustomQuest to market Diabetain™ and OmiWafer™

Novi, Michigan, March 24, 2015– Omni One, LLC has signed an agreement with CustomQuest to distribute Diabetain™ and OmiWafer™ to its customers in the US.

“We welcome and are very excited about this arrangement and associated opportunities. CustomQuest is a reputable organization. Under the leadership of its CEO, Mr. Rick Kantor, CusotmQuest has served its customers for decades with the highest integrity.” Said Charles Liu, CEO of Omni One.

Omni One, LLC which markets Diabetain™ and OmiWafer™ in the US has several clinical studies conducted on its products. Diabetain™ is a blood sugar lowering, energy boosting, vitamin supplement for diabetes patients and healthy individuals. OmiWafer™ is a no-sugar added Belgium chocolate snack wafer with prebiotic, vitamins and green tea to boost energy for diabetes patients.

CustomQuest is a Cincinnati-based full service distributor. Its customer list includes: Wal-Mart, CVS, Walgreen, Ride-Aid, Kroger, Target, Sears/Kmart, Ralphs, Win Dixie, Cardinal and McKesson.

Contact information
Charles Liu, CEO
Omni One, LLC
248-921-1393
Cliu@omnifend,com
www.Diabetain.com

Omni One, LLC signed an agreement today with Automated Management, LLC

Posted by

Omni One, LLC signs agreement today with Automated Management to distribute Diabetain™ and OmiWafer™

Novi, Michigan, March 24, 2015– Omni One, LLC has signed an agreement with Automated Management to distribute Diabetain™ and OmiWafer™ to its customers in the US.

“Automated Management is a specialty distributor serving Micro-Markets, C Stores, vending machines, airport shops, office coffee services, hotel pantries, college and university bookstores, cafeterias, and Fedex/Kinkos locations. We believe this agreement compliments the agreement with CustomQuest in addressing the market needs in the US. We are very pleased and looking forward to working with Automated Management.” Said Charles Liu, CEO of Omni One.

Omni One, LLC which markets Diabetain™ and OmiWafer™ in the US has several clinical studies conducted on its products. Diabetain™ is a blood sugar lowering, energy boosting, vitamin supplement for diabetes patients and healthy individuals. OmiWafer™ is a no-sugar added Belgium dark chocolate snack wafer with prebiotic, vitamins and green tea to boost energy for diabetes patients.

Automated Mangement, LLC is based in Florida, engaged in the business of marketing a variety of products. Its customer list includes: Macy’s, B & N Book Stores, Bed Bath and Beyond, Camping World, Dick’s Sporting Goods, FedEx Stores, Hallmark, Staples, And Vitamin Shoppe and many others.

Contact information
Charles Liu, CEO
Omni One, LLC
248-921-1393
Cliu@omnifend,com
www.Diabetain.com

Omni One, LLC signs agreement today with Con-Temp

Posted by

Omni One, LLC signs agreement today with Con-Temp, Inc. to supply Diabetain and OmiWafer for distribution via Automated Management, Inc.

Novi, Michigan, January 15, 2015–Omni One, LLC has agreed to supply Diabetain and Omiwafer to Con-Temp, Inc. in 2015. Con-Temp will act as an intermediate company to coordinate the supply chain activities with Automated Management, Inc.

“This agreement will place our products in the space where consumers are already captivated. We are very excited about this opportunity.” Said Charles Liu, CEO of Omni One.

Omni One, LLC which markets Diabetain and OmiWafer in the US has several clinical studies conducted on its products. Diabetain is a blood sugar lowering, energy boosting vitamin supplement for diabetes patients and healthy individuals. OmiWafer is a no-sugar added Belgium chocolate snack wafer with prebiotic and vitamins and green tea to boost energy for all consumers.

Con-Temp, Inc is a marketing company which has an exclusive contract with Automated Management Inc. to supply Omni One’s health care products. Automated Management Inc. operates marketing and sales activities in 4,900 universities and college bookstores, 151,282 convenient stores including 7-Eleven, 30,000 automated vending machines including Canteen, and 6 M potential vending locations in the US.

Contact information

Charles Liu, CEO

Omni One, LLC

248-921-1393

Cliu@omnifend,com

www.Diabetain.com

Omni One, LLC Receives Letter of Intent (LOI)

Posted by

Novi, Michigan — SinoPharm of China has issued a letter of intent (LOI) to import Diabetain™ and its related technology and other diabetes products from Omni One. This letter of intent stipulates a close collaboration between two companies and implementing a clinical trial in China for a “package drug” status. Diabetain will be sold in SinoPharm’s many well established distribution chennels in China in 2016. The diabetes diseaase is on the rise in China over the last decade.  It is estimated total number of diabetes patients in China is about 100 million. Chinese government have placed diabetes as one of its core health problem recently.

“Diabetain’s efficacy as an adjunct therapy with metformin and other oral anti-diabetic medications will help containing health care costs and make it much more affordable. We welcome the opportunity to partnering with SinoPharm. We foresee this opportunity will lead us to other markets in Asia and Europe,” said Charles Liu, Omni One’s CEO.

China National Pharmaceutical Surgical Group Corporation a.k.a.SinoPharm is the largest pharmaceutical and health care group under state owned assets supervision and administration commission of state consul in China.

SinoPharm manufactures patent medicines, blood products and traditional Chinese medicine. It’s estimated revenue in 2013 was US $20-30 billion.

Omni One, LLC is a Novi-based Michigan company with an innovative and comprehensive product pipeline in the field of alternative diabetes management and related diseases.

For more information about this news release contact Charles Liu at 248-921-1393 or CLIU@DIABETAINC.COM.

Omni One Files U.S. Patent on Diabetain™

Posted by

Novi, Michigan — Omni One, LLC, with the support of Michigan Business Accelerator Fund (BAF), has filed a U.S. patent with 26 claims on its product Diabetain™, titled “Nutriceutical combination for prevention and treatment of Type 2 diabetes” on August, 18, 2014. The documents were prepared by its attorneys at Butzel Long based in Detroit, Michigan.

Diabetain is the only herbal diabetes-specific supplement designed and formulated by a pharmacist and studied in two separate clinical trials in the U.S. Diabetain reduces fasting blood glucose and A1c (a three months glucose management track indicator) and it will be launched in 2015.  The rights granted by a U.S. patent extent throughout the territory of the United States and a PCT filing generally has the same effect as a regular national patent application in each PCT-member countries once additional documents filed and fees paid in each countries within 18 months.

Butzel Long is a leading law firm with offices located in Michigan, New York City, Washington D.C. and alliance offices in Mexico and China. Founded in 1854, Butzel Long is one of the oldest firms in the Midwest having played a prominent role in the development and growth of several major industries business leaders has turned to it for highly effective legal counsel for over 155 years.

Omni One, LLC is a Novi-based Michigan company, which has a comprehensive product pipeline in the field of alternative diabetes management and related diseases.

For more information about this news release contact Charles Liu, at 248-921-1393 or cliu@diabetainc.com.